SUPPLEMENTARY PROCEDURE
Briefly, 1-3 µl cDNA (1:10 diluted final amount of 10-30 ng) and gene specific primers (probes, when assays with probes) were used in each reaction with total volume of 25 µl. For each assay (one gene expression analysis), the same amount of cDNA was used for analysis, high abundant genes were assayed with the lower amount of cDNA while the lower abundant genes were assayed with the higher amount of cDNA. For the QuantiTect assays, we used QuantiTect T M Custome Assay (Qiagen Inc., Valencia, CA, USA) (Supplementary Table 2 ), which was added to QuantiTect (Probe/SYBR Green) PCR Master Mix (Qiagen Inc., Valencia, CA, USA). For the assays with designed primers, we used the iQ-SYBR Green Supermix (BioRad, Hercules, California, USA).
Absence of DNA contamination was verified by amplifying the house-keeping gene, R18S. The products were visualized on gel-electrophoresis to observe no product. Minus reverse transcribed (RT) samples were tested simultaneously with experimental samples.
Real-time PCR was performed in the iCycler iQ system (BioRad Co., Hercules, CA, USA). The amplifications were conducted on the real-time thermocycler:
For assays with primers the following program scheme was used: 1 cycle at 95
• C for 3 min, 35-45 cycles at 95
• C for 10 s and T-annealing for 45 s, 1 cycle at 95
• C for 1 min, 1 cycle at 55
• C for 1 min, 80 cycles beginning at 55
• C and increasing each cycle by 0.5 • C for melting point analysis. All PCR reactions were run in duplicate.
For assays using the QuantiTect assay, we used the PCR amplification scheme as indicated in the manual (Qiagen, Hilden, Germany).
SUPPLEMENTARY
All subjects underwent formal diagnostic procedure according to the NINCDS-ADRDA criteria [1] . Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) [2, 3] , MMSE [4] , and Clinical Dementia Rating (CDR) [5] were administered to all subjects. The MMSE was used for following up the progression, while the other two were used for rough estimation of the diagnosis assessment. Further information was obtained by Unified Parkinson Scale [6] . Depressive and anxiety symptoms were assessed with Hamilton Depression Scale [7] , Short Geriatric Depres- Manual, according to the manual (Qiagen). Bold, house-keeping genes used for normalization. The mean values and standard deviations are calculated over all time points and patients. The analyses were repeated twice; once age was included as continuous variable and once age was subdivided in eight groups. The resulting p-values of the genes did not differ in both methods.
sion Scale [8] and State Trait Anxiety Inventory (X1, X2) [9] . These scales were used in order to rule out subjects with sever neurologic of psychiatric disorders (data not shown). In addition, detailed information on medication and smoking habits were collected. Continuous decrease of cognitive and mnestic functions is typical in Alzheimer's disease, as can be seen in most of the subjects. Subject A6 and subject A11 showed at assessment period-III and subject A17 showed at assessment period-II unspecific symptoms of physical diseases. Subject A9 underwent surgery some days before assessment. At assessment period-I and period-II, the same 10 subjects took anticholinergic drugs but only two of them have increased dosage. At assessment period-II, an additional four subjects that were assessed the first time took anticholinergic drugs. At assessment period-III, again, 14 subjects took anticholinergic drugs while two discontinued anticholinergic medication, two started medication, and one decreased dosage. At assessment period-IV, one of these subjects had discontinued anticholinergic medication, and one had decreased dosage. At all four assessment periods, all the subjects underwent pharmacological treatment with the exception of two healthy controls. 69  1  0  29  -29  29  A26  83  1  0  29  29  --A27  68  0  0  28  29  30  30  A28  77  0  0  30  30  30  30  A29  57  0  0  30  30  30  30  A30  61  1  0  29  29  28*  29*  A31  74  0  0  30*  30*  30  30  A32  77  0  0  30  30  30  30  A33  79  1  0  30  29  30  30  A34  63  1  0  30  30  30  30  A35  65  0  0  30  -30  30  A36  67  1  0  30  -30  -A37  80  0  0  28  29  30  29  A38  65  0  0  30  30  30  30  A39  69  1  0  30  30  30  30  A40  82  1  0  29  30  30  29  A41  59.5  0  0  -28  30*  29*  A42  59.5  1  0  -30  30  30  A43  64  1  0  30  30  30  30  A44  58  0  0  30  30  -30  A45  95  0  0  29  29  29  30  A46  79  0  0  30  30  30  30  A47  74  0  0  30  30  30  30  A48  75  1  0  30  30  -A49  65  1  0  30  30  30  30  A50  66  0  0  30  30  30  30  A51 77 
